Customer concentration
A limited number of commercial programs can materially affect revenue if one account slows or ends.
- Scope
- Kardium Globe® and related medtech customers
- Materiality
- high
Corline Biomedical
Corline Biomedical is a Swedish medical technology company focused on CHS™, a heparin-based surface technology used to make blood-contacting medical devices more biocompatible. The company develops and supplies products, reagents, and licensing-based solutions for device manufacturers, with a commercial focus in cardiovascular and catheter-based applications.
| % | |
|---|---|
| CHS™ surface technology | 55% Heparin-based surface technology used to improve blood compatibility in medical devices. |
| Products and reagents | 35% Commercially supplied products and reagents used in coating and device workflows. |
| Licensing and supply agreements | 10% Longer-term agreements that grant customers rights to use Corline's technology and supply chain. |
Corline sells primarily to medical device companies that need blood-compatible surfaces for catheters and other...
- PFA catheter manufacturersprimary
Buy CHS™-enabled solutions for pulsed field ablation catheter systems because blood compatibility is critical in cardiac procedures.
- Medical device OEMsprimary
Purchase products, reagents, and technology access for blood-contacting devices that need antithrombotic surface treatment.
- Existing commercial accountssecondary
Buy recurring products and reagents used in ongoing device production and development workflows.
- Prospective medtech adoptersemerging
Evaluate CHS™ as a standard surface solution for broader device categories beyond the current core accounts.
Corline is headquartered in Sweden and appears to operate as a small, internationally oriented medtech supplier...
- •Sweden is the corporate base and reporting center
- •U.S. market is strategically important for CHS™ commercialization
- •Business is tied to global medtech OEM supply chains
- •Customer programs can span multiple geographies and regulatory regimes
Corline's strategy is to expand commercial deliveries of products and reagents while broadening CHS™ adoption across...
01
Expand commercial product and reagent deliveriesshort-term
Recurring commercial sales improve visibility and support broader adoption of the technology.
02
Scale the Kardium Globe® PFA programmedium-term
A successful platform relationship can anchor volume and validate CHS™ in a fast-growing market.
03
Broaden CHS™ into additional medtech accountsmedium-term
A wider customer base reduces dependence on any single program and expands addressable demand.
Corline depends on successful customer qualification, regulatory approvals, and adoption of its CHS™ technology in a...
Regulatory and product approval risk
Medical device adoption depends on approvals, validation, and customer qualification cycles.
- Scope
- PFA and catheter-based applications
- Materiality
- high
Technology adoption risk
CHS™ must prove performance and reliability across customer programs before scaling broadly.
- Scope
- New medtech customer adoption
- Materiality
- high
Market concentration in PFA
A meaningful part of the growth case is tied to one fast-growing but specialized end market.
- Scope
- Pulsed field ablation
- Materiality
- medium
Revenue recognition timing
Can cause quarter-to-quarter volatility in reported revenue
Revenue mix between products and other activities
Affects gross margin profile and comparability
Small-base quarterly comparability
Makes trend analysis sensitive to one-off deliveries
: 11/08/2026